FindTrial
Sign In

Atorvastatin in Myeloma

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00164086
Enrollment
Unknown
Registered
2005-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2006-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloma

Brief summary

The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.

Interventions

DRUGatorvastatin

Sponsors

Bayside Health
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Myeloma in remission

Exclusion criteria

* Adverse events (AEs) to statin, already on a statin, or contraindication to statin

Countries

Australia

Contacts

Primary ContactDr Jennifer Martin, MBChB, FRACP
jennifer.martin@med.monash.edu.au0405 341 676

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026